A Phase II Window Study of Front-line Axitinib Followed by Axitinib and Radiation for Elderly Patients With Glioblastoma Multiforme (GBM)
The addition of axitinib to standard treatment is experimental and has not been approved by
the United States Food and Drug Administration (FDA). Axitinib works by preventing new blood
vessels from forming, and tumors need to make new blood vessels in order to grow. The study
will find out what effects, good or bad, axitinib has on the tumor. In addition, this study
will try to determine whether the response to axitinib and the overall outcome depends on
certain characteristics of your tumor.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
overall survival
average 1 year
No
Olivier Rixe, MD, PhD
Principal Investigator
University of Cincinnati
United States: Food and Drug Administration
UCCR-2
NCT01508117
January 2012
June 2016
Name | Location |
---|---|
University of Cincinnati | Cincinnati, Ohio 45267-0502 |